Current version snapshot

FDA-approved↗↗↗Metabolic↗

Current · version 4: Insulin glargine-aldy↗

Related names recorded in this version: Langlara↗

A long-acting insulin glargine product licensed by FDA as Langlara in April 2026 to improve blood-sugar control in adults and children with diabetes.↗↗↗

This immutable URL preserves the current public version.
The canonical profile remains the primary reading view. Read the canonical profile.
Update · November 16, 2026

We now state that the label calls Langlara biosimilar to Lantus, and that the trials in its label are the reference product’s trials, which the Lantus label describes as trials of Lantus. We also no longer suggest that an unread page of the approval letter might hold FDA’s findings: it does not. 143

What this version reported

Its label states that it is biosimilar to Lantus. The trials in the label are the insulin glargine trials against NPH insulin, which the Lantus label describes as trials of Lantus; no trial of insulin glargine-aldy itself is described in the sources reviewed here.↗↗↗

Organizations named in cited records:
  • U.S. National Library of Medicine↗
  • U.S. Food and Drug Administration↗↗

Reader guide in this version

Key takeaway

Insulin glargine-aldy is a long-acting insulin, sold as Langlara, that FDA licensed on April 29, 2026 to improve blood-sugar control in adults and children with diabetes.1,2,3 Its label states that Langlara is biosimilar to Lantus (insulin glargine), meaning it was approved on data showing it is highly similar to Lantus with no clinically meaningful differences.1 The clinical trials in its label are the insulin glargine trials against NPH insulin, which the Lantus label describes as trials of Lantus. No trial run with insulin glargine-aldy itself is described in the sources reviewed here.1,4

At a glance

What it is
A long-acting insulin glargine product that its label states is biosimilar to Lantus. The label states that insulin lowers blood sugar by helping muscle and fat take up glucose and by reducing the liver’s glucose output.1
FDA status
FDA-approved. Drugs@FDA lists Langlara, application BLA761412, with an approval date of April 29, 2026. The cited label has no boxed warning.1,2
Human evidence
Large randomized trials of Lantus, the reference product, compared with NPH insulin. The Langlara label summarizes them as insulin glargine studies; they are not trials of insulin glargine-aldy.1,4
Evidence strength
Large randomized human trials

What is insulin glargine-aldy?

Insulin glargine-aldy is an insulin glargine product, a lab-made long-acting form of insulin. Drugs@FDA lists it as Langlara, from Sunshine Lake Pharma, under application BLA761412.1,2

FDA’s approval letter states that the application was submitted under section 351(k) of the Public Health Service Act and describes it as seeking licensure as biosimilar to and interchangeable with US-licensed Lantus.3

The Langlara label states that it is biosimilar to Lantus, and explains that a biosimilar is approved on data showing it is highly similar to an FDA-approved reference product with no clinically meaningful differences.1

How does insulin glargine-aldy work?

The label states that the main action of insulin, including insulin glargine products, is to regulate glucose metabolism.1

According to the label, insulin lowers blood sugar by stimulating glucose uptake, especially by muscle and fat, and by reducing glucose production by the liver.1

What do human studies show?

The Langlara label summarizes open-label, randomized trials that compared insulin glargine with NPH insulin in 2,327 adults and 349 children with type 1 diabetes and 1,563 adults with type 2 diabetes.1

The Lantus label describes the same trials, with the same numbers, as trials of Lantus. They are the reference product’s trials, not trials of insulin glargine-aldy.1,4

In general, the reduction in HbA1c, a measure of long-term blood sugar, with insulin glargine was similar to that with NPH insulin, according to both labels.1,4

What the evidence base contains

  • Large randomized human trial Open-label randomized trials of insulin glargine compared with NPH insulin in 2,327 adults and 349 children with type 1 diabetes and 1,563 adults with type 2 diabetes. The Langlara label summarizes them, and the Lantus label describes the same trials, with the same numbers, as trials of Lantus, the reference product. The largest single trial enrolled 619 adults.1,4

Evidence-strength label: Large randomized human trials. How this label is assigned

Is insulin glargine-aldy FDA-approved?

Yes. Drugs@FDA lists Langlara, application BLA761412, with an approval date of April 29, 2026.2

FDA’s approval letter licenses Langlara and states that it is indicated to improve glycemic control in adults and pediatric patients with diabetes mellitus.3

The Langlara label cited here (DailyMed SPL version 5, published July 8, 2026) states the same indication, states that Langlara is biosimilar to Lantus, and states that it is not recommended for treating diabetic ketoacidosis.1

The label has no boxed warning. It states that the product is contraindicated during episodes of low blood sugar and in people allergic to any insulin glargine product or its ingredients.1

Its warnings cover low or high blood sugar after changes in insulin treatment, low blood sugar including from medication errors, allergic reactions, low potassium, and fluid retention and heart failure when used with PPAR-gamma agonists.1

Timeline

  1. FDA approves Langlara, according to Drugs@FDA and FDA’s approval letter.2,3
  2. DailyMed publishes the Langlara label version cited on this page.1

What is still unknown?

The data behind FDA’s decision: Drugs@FDA lists no review documents for this application, and the approval letter does not set out its findings.2,3

Whether FDA found Langlara interchangeable with Lantus: the approval letter says the application sought that, but the label cited here states only that it is biosimilar.1,3

Sources for this version

  1. 1
    LANGLARA (insulin glargine-aldy) injection, solution · SPL version 5 · published 2026-07-08 ↗

    DailyMed · U.S. National Library of Medicine · Official source · Source checked July 22, 2026

  2. 2
    Drugs@FDA application BLA761412 · original submission status AP · 2026-04-29 · dataset 2026-08-13 ↗

    Drugs@FDA via openFDA · Official source · Source checked August 14, 2026

  3. 3
    Langlara (insulin glargine-aldy): BLA 761412 approval letter, April 29, 2026 ↗

    U.S. Food and Drug Administration · Official source · Source checked November 14, 2026

  4. 4
    Lantus (insulin glargine) prescribing information, application 021081 supplements S-078 and S-079, revised June 2023 ↗

    U.S. Food and Drug Administration · Official source · Source checked November 16, 2026